文献速递湿疹皮炎与荨麻疹皮肤肿瘤

成人特应性皮炎患者局部钙调神经磷酸酶抑制剂使用与角质形成细胞癌风险的关联

Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis.
PubMed 文献 · JAMA Dermatol · 2020-01-01

该回顾性队列研究纳入Kaiser Permanente Northern California 93 746例40岁及以上特应性皮炎或皮炎成人患者,比较局部钙调神经磷酸酶抑制剂(TCI)与局部糖皮质激素或未暴露者的角质形成细胞癌(KC)风险。多变量Cox回归显示TCI暴露与总体KC、基底细胞癌(BCC)及鳞状细胞癌(SCC)风险均无显著关联,且风险不随剂量、频率和持续时间改变。

要点

  • TCI暴露与总体KC风险无显著关联(aHR 1.02,95%CI 0.93-1.13)。
  • TCI与局部糖皮质激素相比,BCC和SCC风险均无显著差异。
  • TCI剂量、频率和持续时间与KC风险无关联。

核心结论

  • 成人特应性皮炎患者使用TCI与总体KC、BCC或SCC风险无 apparent 关联。

研究设计与样本

  • 回顾性队列研究,纳入Kaiser Permanente Northern California 93 746例40岁及以上有医生诊断特应性皮炎或皮炎的成人,诊断时间2002年1月1日至2013年12月31日,随访至2017年12月31日。
  • 暴露为研究期间药房发放的TCI(n=7033),主要比较组为局部糖皮质激素(n=73 674),替代比较组为未暴露于TCI或局部糖皮质激素者(n=46 141)。
  • 主要结局为经电子病理检查验证的 incident KC(n=7744)。

主要发现

  • 与局部糖皮质激素暴露相比,TCI暴露与KC风险无关联(aHR 1.02;95%CI 0.93-1.13)。
  • BCC风险(aHR 1.01;95%CI 0.90-1.14,TCI vs 局部糖皮质激素)和SCC风险(aHR 0.94;95%CI 0.82-1.08,TCI vs 局部糖皮质激素)均无显著差异。
  • 以未暴露个体为比较组,BCC风险结果相似(aHR 1.04;95%CI 0.91-1.19,TCI vs 未暴露)。
  • TCI剂量、频率和使用持续时间与BCC、SCC或总体KC风险之间无关联。

临床怎么用

  • 在成人特应性皮炎患者中,TCI使用可能就KC风险而言是安全的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Topical calcineurin inhibitors (TCIs), primarily used to treat atopic dermatitis (AD), carry a black box label warning users about the potential for increased skin cancer risk. The risk associated with keratinocyte carcinoma (KC), the most common cancer, defined as basal cell carcinoma (BCC) and squamous cell carcinoma (SCC), remains poorly defined because findings from large-scale postmarketing surveillance studies have not been reported. OBJECTIVES: To examine KC risk overall and by subtype (BCC and SCC) among adults with AD exposed to TCIs compared with those exposed to topical corticosteroids (primary comparator group) and those unexposed to TCIs or topical corticosteroids (alternative comparator group) as well as alterations in risk with TCI dose, frequency, and duration of exposure. DESIGN, SETTING, AND PARTICIPANTS: A retrospective cohort study was conducted at Kaiser Permanente Northern California, a large, integrated health care delivery system, of adults 40 years or older (n = 93 746) with a physician-rendered diagnosis of AD or dermatitis. Patients who were diagnosed from January 1, 2002, to December 31, 2013, were included, with follow-up through December 31, 2017. Data analysis was conducted from June 1, 2016, to October 1, 2018. EXPOSURES: Time-varying pharmacy-dispensed TCI exposure (n = 7033) over the study period was compared with topical corticosteroids (n = 73 674) and no TCI or topical corticosteroid exposure (n = 46 141). MAIN OUTCOMES AND MEASURES: Electronic pathologic testing-validated incident KCs (n = 7744). RESULTS: Among a cohort of 93 746 members, the mean (SD) age was 58.5 (12.7) years, and 55 023 patients (58.7%) were women. Multivariable Cox proportional hazards regression revealed no association between TCI exposure and KC risk (adjusted hazard ratio [aHR], 1.02; 95% CI, 0.93-1.13) compared with topical corticosteroid exposure. Similarly, there were no significant differences in BCC risk (aHR, 1.01; 95% CI, 0.90-1.14, TCI vs topical corticosteroids) or SCC risk (aHR, 0.94; 95% CI, 0.82-1.08, TCI vs topical corticosteroids). Changing the comparator group to unexposed individuals yielded similar findings (aHR, 1.04; 95% CI, 0.91-1.19, TCI vs unexposed for basal cell carcinoma). There were no associations between TCI dose, frequency, and duration of use and BCC, SCC, or overall KC risk. CONCLUSIONS AND RELEVANCE: The results of this postmarketing surveillance study of adult health plan members with AD revealed no apparent association between TCI exposure and overall KC, BCC, or SCC risk. Secondary analyses examining dose, frequency, and duration of TCI exposure revealed no associations. These findings suggest that use of TCIs may be safe with respect to KC risk among adults with AD.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Asgari MM, Tsai AL, Avalos L, et al. Association Between Topical Calcineurin Inhibitor Use and Keratinocyte Carcinoma Risk Among Adults With Atopic Dermatitis. JAMA Dermatol. 2020. PMID: 32785626. doi:10.1001/jamadermatol.2020.2240

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。